New drug hope to stop dangerous transplant complication in kids
NCT ID NCT03842696
Summary
This study is testing if adding a drug called vorinostat to standard medications can better prevent graft-versus-host disease (GVHD) in children and young adults getting a bone marrow transplant for blood cancers. GVHD is a serious complication where the donor's immune cells attack the patient's body. The research aims to find the safest and most effective dose of vorinostat and see if it reduces the rate of severe GVHD after the transplant.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Emory University
Atlanta, Georgia, 30322, United States
-
Henry Ford Hospital
Detroit, Michigan, 48202, United States
-
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Indianapolis, Indiana, 46202, United States
-
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
University of Colorado
Aurora, Colorado, 80045, United States
-
University of Michigan Health System
Ann Arbor, Michigan, 48109, United States
-
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, 37232, United States
Conditions
Explore the condition pages connected to this study.